Skip to main content
Innovent Biologics, Inc. logo

Innovent Biologics, Inc. — Investor Relations & Filings

Ticker · 1801 ISIN · KYG4818G1010 LEI · 25490058ONL9SCIE1R22 HKEX Manufacturing
Open in API
Filings indexed 442 across all filing types
Latest filing 2026-04-30 Earnings Release
Country KY Cayman Islands
Listing HKEX 1801

About Innovent Biologics, Inc.

http://www.innoventbio.com

Innovent Biologics, Inc. is a biopharmaceutical company established in 2011, dedicated to the development, manufacturing, and commercialization of high-quality innovative medicines. The company specializes in creating biopharmaceutical drugs, including monoclonal antibody candidates, primarily targeting major therapeutic areas such as oncology and cardiovascular diseases. Innovent operates with a mission to deliver high-quality biopharmaceuticals that are affordable. Its research efforts are supported by the Innovent Academy, a platform focused on drug discovery and pioneering innovations.

Recent filings

Filing Released Lang Actions
INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE FIRST QUARTER OF 2026
Earnings Release Classification · 1% confidence The document is a Hong Kong Exchanges “inside information” announcement providing first quarter 2026 product revenue figures and growth highlights. It is not a full interim report with financial statements but an initial quarterly financial result update (key highlights only). Therefore it aligns with an Earnings Release. Q1 2026
2026-04-30 English
2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Environmental & Social Information Classification · 1% confidence The document is the 2025 Environmental, Social and Governance Report issued by Innovent Biologics. It focuses entirely on ESG governance, climate change, resource conservation, social responsibility, stakeholder engagement, and sustainability metrics. The structure follows ESG reporting frameworks (HKEX ESG Reporting Code, GRI, SASB, MSCI) rather than financial performance or regulatory announcements. This aligns directly with the definition of an Environmental & Social Information report.
2026-04-28 English
2025 ANNUAL REPORT
Regulatory Filings
2026-04-28 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Share Issue/Capital Change Classification · 1% confidence The document is a standardized monthly return (Form FF301) filed under HKEX Listing Rules Chapter 19B, detailing movements in authorised share capital, issued shares, share options, convertibles, and other capital changes for the month ending 31 March 2026. This is not an annual or interim financial report, earnings release, or dividend notice, but a regulatory announcement of share capital changes and share issues (e.g., exercise of options). It therefore falls under the category of share issue/capital change.
2026-04-09 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARES
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory listing announcement by Innovent Biologics on the HKEX regarding the grant of share options and restricted shares under its 2024 Share Scheme. It details the number of options and restricted shares granted, grant dates, vesting schedules, performance targets, clawback mechanisms, and allocations to directors and employees. This constitutes an issuance of new shares (or rights to future issuance) and is not a share repurchase, director personal dealing, or general financial report. It therefore best fits the "Share Issue/Capital Change" category (SHA).
2026-03-31 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025
Earnings Release Classification · 1% confidence The document is titled “ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025” and contains audited consolidated results, financial highlights, and business highlights. It reads as an initial press‐style release of annual financial performance, rather than the full statutory annual report (which would include detailed financial statements, notes, governance reports, etc.). It is not a short notice merely indicating a report is available. Therefore, it fits the definition of an Earnings Release (ER). FY 2025
2026-03-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.